Have a research question to share or an article to highlight?
A piece to write about neuroscience, eye tracking or neuroClues?
Let’s connect.
The company announces a €10 million Series A to accelerate one of the fastest clinical rollouts in European neurotech, while concurrently securing additional non-dilutive funding, bringing the total capital raised by neuroClues to €25 million.
Join the neuroClues crowdfunding campaign on LITA and become a shareholder.
Discover how the biomarkers extracted with neuroClues® may support assessment and monitoring in concussion
Discover the data behind diagnostic variability and why we believe biomarkers, including oculomotor ones, could be part of the way forward.
Discover the reliability of oculomotor biomarkers and how consistent eye movement metrics support early detection of neurological disorders
Learn more about how neuroClues® eye movement biomarkers could support early detection of cognitive impairments.
Learn more about the differences between voluntary and reflexive saccades, the structures involved in those movements, and how they can provide interesting clues about brain health.
Learn more about neuroClues®’ role in the ICEBERG cohort with 50 patients recorded, and how eye movement analysis is advancing cognitive impairment detection.
Volgende stap: neuroClues op de Europese markt lanceren en de “stethoscoop van de hersenen” worden Samengevat neuroClues behaalt MDR-certificering (Medical Device Regulation) en mag
In summary neuroClues achieves Medical Device Regulation (MDR) certification and is now allowed to issue the CE-mark on its Class IIa medical device designed
Book a custom virtual walk-through of NeuroClues with one of our experts and see how our innovative eye-tracking technology could impact your clinical practice.
